Polar Capital raises Nephrocare stake to 8.31% via off-market deal
- Polar Capital Funds PLC increased its aggregate stake in Nephrocare Health Services to 8.311%
- The acquisition involved 2,549,478 shares purchased via off-market placing on September 24, 2026
- Healthcare Opportunities Fund accounted for 2,545,719 of the total shares acquired
- Total voting capital remained unchanged at 100,559,014 equity shares
*this image is generated using AI for illustrative purposes only.
Nephrocare Health Services Ltd saw its shareholding structure shift as Polar Capital Funds PLC increased its aggregate holding to 8.311% following an off-market acquisition.
The transaction, executed on September 24, 2026, involved the purchase of 2,549,478 equity shares carrying voting rights. This move was undertaken by three specific funds under the Polar Capital umbrella: Healthcare Opportunities Fund, Emerging Markets Healthcare Fund, and Healthcare Discovery Fund. The disclosure confirms that the acquirer does not belong to the promoter or promoter group category.
Acquisition details and fund breakdown
The bulk of the acquisition was driven by the Healthcare Opportunities Fund, which purchased 2,545,719 shares, representing a 2.532% increase in its individual holding. The other two funds added marginal quantities: the Emerging Markets Healthcare Fund bought 573 shares (0.001%) and the Healthcare Discovery Fund acquired 3,186 shares (0.003%).
Prior to this transaction, the combined holding of these three funds stood at 5.057%. The post-acquisition figures reflect the new consolidated position across all three entities.
| Fund Name | Pre-Acquisition Holding (%) | Shares Acquired | Post-Acquisition Holding (%) |
|---|---|---|---|
| Healthcare Opportunities Fund | 5.042% | 2,545,719 | 8.280% |
| Emerging Markets Healthcare Fund | 0.009% | 573 | 0.017% |
| Healthcare Discovery Fund | 0.006% | 3,186 | 0.014% |
| Total Aggregate Holding | 5.057% | 2,549,478 | 8.311% |
Capital structure and regulatory context
The equity share capital and total voting capital of the target company remained unchanged at 100,559,014 equity shares both before and after the acquisition. Similarly, the total diluted share/voting capital stood at 100,559,014 equity shares, indicating no dilution from convertible instruments or warrants during this period.
The acquisition was conducted through an off-market placing mode. The disclosure was signed in London, UK, and dated September 28, 2026. The filing adheres to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
What the numbers show
The data reveals a highly concentrated accumulation strategy within the Polar Capital group. While the aggregate stake rose by 2.535% (from 5.057% to 8.311%), nearly 99.8% of the newly acquired shares were absorbed by a single entity, the Healthcare Opportunities Fund. The other two funds' contributions were negligible, suggesting that the primary conviction play on Nephrocare is isolated within the Opportunities mandate rather than being a broad-based increase across the firm's healthcare portfolio.
Historical Stock Returns for Nephrocare Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.44% | -2.01% | -16.41% | +9.73% | +30.37% | +30.37% |
Will Polar Capital's increased stake in Nephrocare trigger further accumulation toward the 10% threshold, potentially requiring additional regulatory disclosures?
How might the concentrated conviction of the Healthcare Opportunities Fund influence Nephrocare's strategic direction or governance expectations?
What impact could this significant institutional endorsement have on Nephrocare's stock liquidity and valuation multiples in the near term?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
